United Thereutics对Tyvaso治疗特发性肺纤维化的结果激增

2026-03-30 23:41

United Therapeutics is up ~12% in Monday morning trading after reporting positive results in a pair of studies examining Tyvaso (treprostinil) for idiopathic pulmonary fibrosis.
In TETON-1, Tyvaso met the primary endpoint, superiority over placebo for the change in absolute forced vital capacity by 130.1 mL from baseline to week 52.
Also, Tyvaso reduced the risk of clinical worsening and met secondary endpoints compared to placebo, such as time to first acute exacerbation of IPF and changes in percent predicted forced vital capacity.
Analyses of TETON-1 and TETON-2 demonstrated significant treatment effects compared to placebo from baseline to week 52 for change in absolute FVC by 111.8 mL.
The company plans to pursue priority review of an sNDA for the IPF indication, with a submission eyed by the end of the summer.
Tyvaso is currently approved for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

More on United Therapeutics